CHMP Backs Aflibercept (Eylea) for Visual Impairment Caused by CRVO

by Medscape • 2013/07/30 • 0 Comments

The therapeutic indications for aflibercept (Eylea, Bayer Pharma AG) should include treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion in adults.
International Approvals

← AMA urges physicians to report conflicts of interest prior to Sunshine Act deadline

Age-Related Eye Disease Study 2 (AREDS2) Ancillary Spectral Domain Optical Coherence Tomography (A2A_SDOCT) Extension Study →

Post navigation